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Abstract
Background: Population-based patterns of care studies are important for monitoring cancer care but conducting
them is expensive and resource-intensive. Linkage of routinely collected administrative health data may provide an
efficient alternative. Our aim was to determine the accuracy of linked routinely collected administrative data for
monitoring prostate cancer care in New South Wales (NSW), Australia.
Methods: The NSW Prostate Cancer Care and Outcomes Study (PCOS), a population-based survey of patterns of
care for men aged less than 70 years diagnosed with prostate cancer in NSW, was linked to the NSW Cancer
Registry, electronic hospital discharge records and Medicare and Pharmaceutical claims data from Medicare
Australia. The main outcome measures were treatment with radical prostatectomy, any radiotherapy, external beam
radiotherapy, brachytherapy or androgen deprivation therapy, and cancer staging. PCOS data were considered to
represent the true treatment status. The sensitivity and specificity of the administrative data were estimated and
relevant patient characteristics were compared using chi-squared tests.
Results: The validation data set comprised 1857 PCOS patients with treatment information linked to Cancer
Registry records. Hospital and Medicare claims data combined described treatment more accurately than either
one alone. The combined data accurately recorded radical prostatectomy (96% sensitivity) and brachytherapy (93%
sensitivity), but not androgen deprivation therapy (76% sensitivity). External beam radiotherapy was rarely captured
(5% sensitivity), but this was improved by including Medicare claims for radiation field setting or dosimetry (86%
sensitivity). False positive rates were near 0%. Disease stage comparisons were limited by one-third of cases having
unknown stage in the Cancer Registry. Administrative data recorded treatment more accurately for cases in urban
areas.
Conclusions: Cancer Registry and hospital inpatient data accurately captured radical prostatectomy and
brachytherapy treatment, but not external beam radiotherapy or disease stage. Medicare claims data substantially
improved the accuracy with which all major treatments were recorded. These administrative data combined are
valid for population-based studies of some aspects of prostate cancer care.
Background
Prostate cancer is the most common cancer in New
South Wales (NSW), Australia’s most populous state,
accounting for 19% of new cancers diagnosed in 2008
[1]. Most men with prostate cancer have localised dis-
ease at diagnosis but there is considerable uncertainty
regarding their optimal treatment [2]. Population-based
patterns of care studies and disease-specific registers are
important for monitoring cancer care but are expensive,
resource-intensive and difficult to justify on a continu-
ous basis. Where cancer registries do not collect treat-
ment data, linkage of routinely collected administrative
health data to registry records may be an efficient way
of monitoring population-wide patterns of cancer care
[e.g. [3,4]]. However there is little published information
regarding the accuracy of cancer treatment information
obtained in this way.
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Outcomes Study (PCOS) collected data from treating
physicians about men who had a first diagnosis of pros-
tate cancer. These data were considered to represent the
true treatment status, the “gold standard” of information.
This was compared with linked administrative data
including cancer registry records, hospital discharge
records and Medicare and Pharmaceutical claims data
from Medicare Australia. Here we report on the accuracy
of the linked, routinely collected administrative health
data for describing patterns of prostate cancer care in
NSW.
Methods
Administrative health data
Data for men who had a first diagnosis of prostate cancer
were obtained from the NSW Central Cancer Registry
(CCR) [5]. All cancers diagnosed in NSW, except for non-
melanoma skin cancers, are notified to the CCR. Informa-
tion collected includes date of diagnosis, cancer site, mor-
phology and spread of disease at diagnosis obtained from
statutory notification forms and pathology reports. The
CCR does not collect treatment data. For this study CCR
records were obtained for NSW men diagnosed with pros-
tate cancer between January 1999 and December 2002.
Spread of disease was classified as localised, regional
spread, distant metastases or unknown according to the
system described by Jensen et al [6]. Cases diagnosed after
death were excluded from this study.
The NSW Admitted Patient Data Collection (APDC)
contains information on all separations from hospital in
NSW [7]. Hospital medical coders abstract individual
patient information from medical records following the
patient’s discharge from hospital. This includes dates of
admission and separation, procedures carried out and
diagnoses relating to the hospital episode. Procedures
were coded using the Medicare Benefits Schedule-
Extended (MBS-E) classification of the International
Classification of Diseases 10th revision, Australian Modi-
fication (ICD-10-AM). Diagnosis information was
recorded as the reason for the hospital episode, or new
or coexisting conditions [8]. Up to 31 procedure codes
and 40 diagnosis codes could be recorded for each case.
We used hospital separation records from July 1998 to
June 2003.
Medicare data [9] included prostate cancer-related
claims for medical services from the Medicare Benefits
Scheme (MBS) and prescription medicines from the
Pharmaceutical Benefits Scheme (PBS), for the period
January 2000 to December 2008. These schemes, both
components of Australia’s national health insurance
arrangements, provide subsidised access to medical ser-
vices and pharmaceuticals for Australian residents.
Patterns of care study data
PCOS collected data on the patterns of care for 1995 men
aged less than 70 years and diagnosed with prostate cancer
in NSW between October 2000 and October 2002 [10].
Potential participants were identified through notifications
to the CCR. Men who were too ill to be interviewed or
who did not speak English were excluded. Ninety-four
percent of participants (n = 1883) consented to have their
information linked to administrative health data. This
represents half of the prostate cancers diagnosed in men
aged less than 70 years during that period.
Clinical data were abstracted from medical notes at least
one year after diagnosis, by either a trained field officer or
the treating doctor using a data abstraction form designed
for the purpose. Clinical disease stage, radical prostatect-
omy (RP) and other surgical procedures, radiotherapy and
androgen deprivation therapy (ADT) were recorded. Clini-
cal disease stage in PCOS was determined from the clini-
cal data available at diagnosis and was based on biopsy
results, prostate-specific antigen levels and digital rectal
examination. It was recorded as tumour size, nodal invol-
vement and presence or absence of metastases; these were
combined to define localised (tumour size T0-T2c and no
known nodal involvement or metastases), non-localised
(T3a-T4 or nodal involvement or presence of metastases)
or unknown stage.
Record linkage
The NSW Department of Health, Cancer Institute NSW
and Cancer Council NSW ethics committees approved
the project and linkage processes. The NSW Department
of Health linked the CCR and APDC records using Auto-
Stan version 4.0J to standardise address information and
AutoMatch version 4.1 (both Matchware Technologies,
Burtonsville, MD, US) to carry out probabilistic match-
ing. This linkage was performed using name, address,
date of birth, date of diagnosis and hospital-recorded
clinical information that identified cases common to both
data sets, and clerical reviews for questionable matches
were undertaken by trained staff within the Department
of Health. The identifiers from these records were then
linked to those from PCOS by the Centre for Health
Record Linkage (CHeReL) [11] using probabilistic match-
ing carried out with ChoiceMaker software (Choice-
Maker Technologies Inc., New York, US). Both certain
and uncertain matches with PCOS were reviewed cleri-
cally by CHeReL linkage officers, resulting in approxi-
mately 0.1% false positive and less than 0.1% false
negative linkages.
PCOS participants provided their Medicare numbers,
allowing for deterministic linkage to MBS and PBS claims
data by Medicare Australia (see Figure 1). Participants also
provided their name and date of birth on a consent form
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w e r em i s s i n gt h e yw e r en o tconsidered for linkage by
Medicare Australia. Furthermore, if the details on the con-
sent form did not match those on the Medicare enrolment
database (e.g. the supplied name did not match the name
corresponding to the Medicare number on the database)
they were not considered for linkage. Additional probabil-
istic linkage to the MBS and PBS data was not possible.
Treatments and procedures
A specialist clinical panel identified relevant codes for
each data set. Radiotherapy treatment was categorised as
external beam radiation therapy (EBRT), brachytherapy,
or either one of these ("any radiotherapy”). EBRT and
brachytherapy treatment were not mutually exclusive.
Diagnosis information from the APDC was also used to
identify cases who had radiotherapy based on diagnosis
codes for the procedure having taken place (e.g. “Radio-
therapy session”) or those describing convalescence or
sequelae of the treatment (e.g. “Radiation proctitis”).
These diagnoses were included as “any radiotherapy”, but
could not be directly identified as either EBRT or bra-
chytherapy. Other Medicare items related to EBRT
(radiation oncologist consultation, pelvic girdle examina-
tion, radiation field setting, radiation dosimetry) were
included and the change in the accuracy of the adminis-
trative data was assessed.
For consistency in the time periods covered by the differ-
ent data sources we included treatment data up to June
2003. Dates for the receipt of ADT were not recorded in
PCOS so we compared all PCOS records to those in the
administrative data with and without restriction to June
2003.
Statistical analysis
Individual patient data from PCOS were compared to
the APDC and MBS claims data for RP and radiother-
apy procedures, to the PBS claims data for ADT (not
captured in the APDC) and to the CCR for disease sta-
ging. The sensitivity and specificity of the administrative
data relative to PCOS data were estimated. Sensitivity
was defined as the probability of an event being
recorded in the administrative data if it was recorded by
PCOS, while specificity was the probability of an event
not being recorded in the administrative data if not
recorded by PCOS. Chi-squared tests compared the sen-
sitivity across patient categories defined by age, stage,
date of diagnosis, place of residence and socioeconomic
status for the postcode of residence, along with self-
reported household income, health insurance status and
level of education. All analyses were carried out in SAS
version 9.1 (SAS Institute Inc., Cary, NC, US).
Results
Ninety-nine percent (n = 1857) of the PCOS partici-
pants who consented to linkage to the administrative
data were matched to CCR records (Table 1). Seventy-
nine percent of these cases linked to records in both the
APDC and Medicare claims data, 14% linked to Medi-
care claims records only, 6% linked to APDC records
only and 1% did not link to records in either.
Radical prostatectomy
The APDC alone captured RPs more accurately than the
Medicare data, but combining the two sources improved
the accuracy of the administrative data (Table 2). The
APDC captured 90% or more of the RPs for almost all
Linked by Centre for 
Health Record Linkage 
NSW Prostate Cancer 
Care and Outcomes 
Study (PCOS) 
Oct 2000 – Oct 2002 
Medicare and 
Pharmaceutical Claims 
data (MBS, PBS) 
Jan 2000 – Dec 2008 
Linked by 
Medicare 
Australia 
NSW Central Cancer 
Registry (CCR) 
Jan 1999 – Dec 2002 
NSW Admitted Patient 
Data Collection (APDC) 
Jul 1998 – Jun 2003 
Linked by 
NSW Health 
Figure 1 Data sources and period covered in the record linkages.
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Page 3 of 7types of patients, with sensitivity lowest for cases living
in outer regional areas (78% vs 93% for cases living in
major cities, p < 0.0001). Sensitivity of the MBS claims
data was highest for men who had no private health
insurance (89% vs 28% for those with private health
insurance, p < 0.0001) and for those living in major
cities (80% vs 55% for those living in outer regional
areas, p < 0.0001). There were 260 cases with RP
recorded in PCOS but not in the MBS claims data, of
whom 73% had data for other MBS claims.
There were 96 men with RP recorded in PCOS but not
in the APDC. Sixteen of these had a non-radical prosta-
tectomy recorded in the APDC corresponding to the date
of RP recorded in PCOS. Including these other types of
prostatectomy, 52% of cases had prostatectomy recorded
in the APDC (92% sensitivity, 100% specificity). Of the
other 80 men, more than half (n = 45) did not link to any
records in the APDC and 6 cases had a hospital admission
at the time of the RP in PCOS but with a different proce-
dure recorded. Forty of the missed cases were treated by
clinicians practising outside NSW or in areas bordering on
other Australian states. Crossing state borders to receive
treatment is common in Australia and is recorded in the
hospital data collection of the state providing the treat-
ment. If a patient had a record of care provided by a doc-
tor in an interstate or border region they were flagged as
potentially having treatment interstate. After excluding
these cases there was no difference in sensitivity of the
administrative data by patients’ place of residence.
For cases with a RP recorded in both the APDC and
PCOS, 85% had the same date, 13% were up to a week ear-
lier in the APDC, 1% were up to a week earlier in PCOS
and 1% had differences larger than this. Similar results
were obtained using Medicare data.
Radiotherapy
While brachytherapy was recorded in the administrative
data with reasonable accuracy, the sensitivity with which
“any radiotherapy” was recorded was diminished by
under-enumeration of EBRT (Table 2). For one quarter of
the men with “any radiotherapy” recorded in the APDC,
information was obtained from the diagnosis fields only.
Including MBS items for radiation field setting and/or
radiation dosimetry (not recorded in the APDC)
Table 1 Characteristics of prostate cancer cases included
in this study, as recorded in PCOS (n = 1857)
n%
Age
<5 0 4 9 3
50-59 627 34
60-69 1181 64
Disease stage
Localised 1617 87
Non-localised 227 12
Unknown 13 1
Geographical area
a
Major city 1135 61
Inner regional 460 25
Outer regional 235 13
Remote/very remote 22 1
Unknown 5 0
Radical prostatectomy 1036 56
Any radiotherapy 578 31
EBRT 530 29
Brachytherapy 120 6
Androgen deprivation therapy 571 31
ADT for non-localised cases 179 79
a Based on Accessibility/Remoteness Index for Australia (ARIA+), using
distance from the place of residence to major service centres
PCOS: Prostate Cancer Care and Outcomes Study; EBRT: External beam
radiation therapy; ADT: Androgen deprivation therapy
Table 2 Accuracy of administrative data sources for ascertaining type of prostate cancer treatment in NSW 2000-2002
(n = 1857)
PCOS APDC Medicare Medicare + APDC
Procedure n % n % Sensitivity Specificity n % Sensitivity Specificity n % Sensitivity Specificity
Radical prostatectomy 1036 56 942 51 91 100 777 42 75 100 996 54 96 100
Any radiotherapy 578 31 152 8 25 100 114 6 19 100 175 9 29 99
Brachytherapy 120 6 102 5 84 100 99 5 82 100 113 6 93 100
EBRT 530 29 14 1 2 100 21 1 3 100 35 2 5 99
EBRT incl. extra items* 530 29 14 1 2 100 508 27 86 96 515 28 86 96
Any RDT incl. extra items* 578 31 152 8 25 100 523 28 85 98 548 30 89 97
Androgen deprivation therapy 571 31 Not recorded 502 27 76 95
Non-localised cases 179 79 Not recorded 151 67 82 90
* Extra items are non-treatment visits/procedures comprising radiation field setting and radiation dosimetry
PCOS: Prostate Cancer Care and Outcomes Study; APDC: Admitted Patient Data Collection; EBRT: External beam radiation therapy; RDT: radiotherapy
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was captured with only a small reduction in specificity
(Table 2). The improvement was not as great using
MBS items for pelvic girdle examination (sensitivity
increased to 80%, 89% specificity) or a radiation oncolo-
gist consultation (85% sensitivity, 79% specificity). The
sensitivity with which EBRT was recorded was higher
for men from major cities (89%) compared with those
from inner regional areas (81%, p = 0.01).
Nineteen cases had brachytherapy recorded in PCOS
but did not have curative brachytherapy recorded in the
APDC. Of these, 6 had another brachytherapy code in the
APDC (single plane brachytherapy or brachytherapy plan-
ning), 6 had a “radiotherapy session” recorded in the
APDC diagnosis fields on a similar date, 3 had a non-
radiotherapy admission recorded on the same date and
the remaining 4 cases were treated by doctors practising
interstate. Including the other brachytherapy codes
increased the sensitivity of the APDC to 89% and the sen-
sitivity of the combined information from the MBS and
APDC to 95%, with no reduction in specificity.
Androgen deprivation therapy
ADT is more likely to be prescribed for non-localised dis-
ease, and the sensitivity of recording in the PBS was higher
for this group than for all cases (Table 2). When all PBS
items relating to ADT (without date restrictions) were
included, the sensitivity increased to 82% and specificity
dropped to 89% for all cases and was 87% and 77% respec-
tively for men with non-localised disease.
Disease stage
Disease stage was unknown in PCOS for 1% of men com-
pared to 34% in the CCR. Localised disease was more
likely to be recorded accurately in the CCR than non-
localised disease (59% and 19% sensitivity respectively)
(Table 3). Sensitivity of recording of localised disease was
highest for younger cases (< 50 years: 76%, 60-69 years:
55%, p = 0.0002). Of the 1219 cases with known disease
stage recorded in both PCOS and the CCR, 90% were
classified as localised in PCOS compared to 85% in the
CCR (87% sensitivity, 37% specificity).
Discussion
The linked administrative data sets were accurate in enu-
merating certain prostate cancer treatments. Around 95%
of surgery and brachytherapy treatments, 86% of EBRT
and 76% of ADT were captured by linking hospital inpati-
ent episodes and Medicare claims data. Supplementing
hospital records with Medicare and Pharmaceutical claims
data substantially improved the accuracy with which sur-
gery, EBRT, brachytherapy and ADT were captured.
Treatment information was more accurate for men resi-
dent in urban areas, possibly due to interstate treatment
data not being available for men in areas near the state
borders.
We assessed the validity of the routinely collected data
by comparing them to patients’ original medical records.
Similar validation studies, including a 1998 NSW breast
cancer study [12] and various North American studies
[13-16], have also shown administrative data record major
surgical procedures well but under-enumerate radiother-
apy treatments. Other US studies compared cancer regis-
try and Medicare data for cancer treatment and found
high concordance for the records found in both data repo-
sitories, but each data repository included patients who
were not captured in the other [17-19].
The under-enumeration of radiotherapy treatment is
expected as it is generally delivered to outpatients. While
Medicare claims accurately identified cases having EBRT,
the items used (radiation field setting and dosimetry)
generally applied to the initial planning of radiotherapy
treatment rather than actual receipt of treatment. While
some people identified this way may not have gone ahead
with the treatment, the specificity of the administrative
data remained over 95% when these items were included,
suggesting that almost all patients did receive treatment.
Future studies would benefit from access to data from
radiation oncology units or clinical cancer registries.
Disease stage was not recorded in the CCR for one in
three prostate cancer cases, significantly limiting inter-
pretation of the appropriateness of prostate cancer care
based on disease stage. For cases with known stage
recorded in both data sets the agreement was only mod-
erate but it was similar to that reported for colorectal
cancer when aggregated to localised or non-localised
stage [20].
Non-linkage is a key reason for differences in recorded
treatments and there are several possible reasons why
PCOS participants were not linked to the administrative
data sets. These include not having any inpatient hospital
episodes in the APDC (e.g. treated outside NSW, never
admitted to hospital), insufficient identifiers to be certain
of linkage or the cancer not being registered in the CCR
Table 3 Comparison of disease stage information for
cases aged less than 70 years at diagnosis (n = 1844)
PCOS stage
a
Localised Non-localised
CCR stage
b n%
c n%
c
Localised 958 59 74 33
Non-localised 143 9 44 19
Unknown 516 32 109 48
Total 1617 100 227 100
a Clinical stage from PCOS, excludes 13 cases with unknown stage
b Spread of disease at diagnosis recorded in the CCR
c Column percent
PCOS: Prostate Cancer Care and Outcomes Study; CCR: Central Cancer Registry
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was used in PCOS. An investigation of the 26 men in
PCOS who did not have a matching CCR record found a
revised diagnosis date may have been outside the study
period for 5 cases. PCOS participants provided their
Medicare numbers for extraction of their Medicare and
Pharmaceutical claims data, but no data were provided
for 7% of these men. The possible reasons for this include
incomplete consent forms precluding linkage, supplying
an incorrect Medicare number for linkage, or the exis-
t e n c eo fm u l t i p l eM e d i c a r en u m b e r sf o ra ni n d i v i d u a l
with claims being recorded against a number that was
not provided to PCOS.
There are numerous advantages of using administrative
data such as these to undertake health services research
and to measure the performance of medical and health
services. Linkage between data sets can add further value
to these resources. Their population coverage ensures
large and representative samples are available for study.
The data are collected and released on a regular basis,
allowing relatively up-to-date monitoring. The costs
involved, both in time and resources needed to undertake
research, also provide a significant incentive to use linked
data rather than intensive data collection from patients
or clinicians.
There are some limitations in using these administrative
data alone. For example, important factors such as patient
performance status, physician recommendations and qual-
ity of life are not recorded. Also active surveillance was
not explicitly recorded. The data used in this study are
now around 10 years old and other treatments are evol-
ving, such as cryotherapy and microwave therapy, and the
ability of administrative data to capture this information is
not yet known and may be limited. Further validation will
be needed as practice changes. More generally, the admin-
istrative data were not collected specifically to describe
patterns of care so they should be used with caution for
this purpose.
Ethical issues may arise regarding linkage of indivi-
dual’s health information. However, projects utilising the
W e s t e r nA u s t r a l i a nD a t aL i n k a g eS y s t e m[ 2 1 ]h a v e
reported several patterns of cancer care studies using
similar data sources [e.g. [3,4,22,23]] without raising
ethical or privacy-related concerns [24]. It has demon-
strated that establishing a privacy-protecting data link-
age facility has actually reduced requests for name-
identified information from health data custodians [25].
Conclusions
Linkage of administrative health data collections to
describe the patterns and outcomes of cancer care offers
considerable efficiencies in time and resources. The data
provided an accurate account of major surgical procedures
for prostate cancer in NSW, but were less accurate for
ADT and disease stage and hospital admissions data alone
were not sufficient to capture treatment with external
beam radiotherapy. Treatment enumeration was substan-
tially improved when hospital records were combined with
Medicare and Pharmaceutical claims data. We believe that
these administrative data are sufficiently accurate for
describing and monitoring surgery and brachytherapy for
men with prostate cancer.
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